MX2018006986A - Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis. - Google Patents

Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.

Info

Publication number
MX2018006986A
MX2018006986A MX2018006986A MX2018006986A MX2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A
Authority
MX
Mexico
Prior art keywords
natriuretic peptide
type natriuretic
peptide variants
treat osteoarthritis
osteoarthritis
Prior art date
Application number
MX2018006986A
Other languages
English (en)
Spanish (es)
Inventor
K Pinkstaff Jason
A O'neill Charles
M Oppeneer Todd
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2018006986A publication Critical patent/MX2018006986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2018006986A 2015-12-08 2016-12-08 Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis. MX2018006986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Publications (1)

Publication Number Publication Date
MX2018006986A true MX2018006986A (es) 2018-09-05

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006986A MX2018006986A (es) 2015-12-08 2016-12-08 Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.

Country Status (17)

Country Link
US (2) US11202819B2 (https=)
EP (2) EP4019038A3 (https=)
JP (1) JP7104625B2 (https=)
KR (1) KR102941538B1 (https=)
CN (1) CN108697766A (https=)
AU (2) AU2016365751B2 (https=)
CA (1) CA3007315A1 (https=)
DK (1) DK3386531T3 (https=)
ES (1) ES2901769T3 (https=)
HR (1) HRP20211908T1 (https=)
HU (1) HUE057083T2 (https=)
IL (1) IL259690B2 (https=)
MX (1) MX2018006986A (https=)
PL (1) PL3386531T3 (https=)
PT (1) PT3386531T (https=)
RU (1) RU2759679C2 (https=)
WO (1) WO2017100400A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3007976C (en) 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
ES3064816T3 (en) 2016-01-08 2026-04-29 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
WO2017118700A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
DK3400019T3 (da) 2016-01-08 2022-10-24 Ascendis Pharma Growth Disorders As CNP-prodrugs med bærerbinding ved ringenheden
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
US11564974B2 (en) 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
BR112020021966A2 (pt) * 2018-04-27 2021-01-26 Remy Biosciences, Inc. dispositivos médicos, veículos de liberação e fabricação dos mesmos
MX2021008708A (es) * 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
WO2022115563A1 (en) * 2020-11-25 2022-06-02 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides
US20240238428A1 (en) * 2021-05-11 2024-07-18 Texas Tech University System Targeted selenium conjugates as countermeasures for viral and cellular pathogens
EP4444341A1 (en) * 2021-12-07 2024-10-16 BioMarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
KR20250098109A (ko) * 2023-12-21 2025-07-01 주식회사 펩트론 나트륨이뇨 펩타이드 유사체 및 이의 용도
CN117801123B (zh) * 2024-02-29 2024-05-03 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
ES2465141T3 (es) * 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
WO2005094890A1 (ja) * 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
EP2217620A2 (en) * 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
PT2432489T (pt) 2009-05-20 2016-12-07 Biomarin Pharm Inc Variantes do péptido natriurético de tipo c
WO2012088608A1 (en) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof

Also Published As

Publication number Publication date
CN108697766A (zh) 2018-10-23
CA3007315A1 (en) 2017-06-15
US20190247467A1 (en) 2019-08-15
EP3386531A2 (en) 2018-10-17
EP3386531B1 (en) 2021-10-13
RU2018124600A (ru) 2020-01-13
ES2901769T3 (es) 2022-03-23
KR102941538B1 (ko) 2026-03-19
US12214015B2 (en) 2025-02-04
AU2016365751B2 (en) 2023-12-21
HUE057083T2 (hu) 2022-04-28
RU2759679C2 (ru) 2021-11-16
WO2017100400A3 (en) 2017-10-26
IL259690B2 (en) 2023-02-01
HRP20211908T1 (hr) 2022-03-04
DK3386531T3 (da) 2022-01-03
JP2019505486A (ja) 2019-02-28
EP4019038A3 (en) 2022-09-28
WO2017100400A2 (en) 2017-06-15
KR20180088459A (ko) 2018-08-03
EP4019038A2 (en) 2022-06-29
IL259690A (en) 2018-07-31
PT3386531T (pt) 2021-12-29
AU2016365751A1 (en) 2018-06-21
PL3386531T3 (pl) 2022-02-28
US11202819B2 (en) 2021-12-21
IL259690B (en) 2022-10-01
AU2024201852A1 (en) 2024-04-11
JP7104625B2 (ja) 2022-07-21
US20220160836A1 (en) 2022-05-26
RU2018124600A3 (https=) 2020-01-13
RU2021132347A (ru) 2022-03-24

Similar Documents

Publication Publication Date Title
MX2018006986A (es) Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
ECSP17021754A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112018001761A2 (pt) uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética
PH12018502664A1 (en) Variant adeno-associated viruses and methods of using
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
ZA201803366B (en) Antibody molecules to april and uses thereof
MX2022003184A (es) Variantes del cnp y sus conjugados.
CL2017001046A1 (es) Inhibidoes del bromodominio
MX2016012880A (es) Cadena j modificada.
BR112016024494A8 (pt) análogo de peptídeo e seu uso
ECSP17003946A (es) Anticuerpos antagonistas del interferón alfa y omega
UY37589A (es) COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)
UY37590A (es) COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
EA202191471A1 (ru) Противовоспалительные полипептиды
MX2020006355A (es) Pirrolidinamidas ii sustituidas.
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
PH12017500426A1 (en) Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
ECSP15014925A (es) Compuestos para tratar el bloqueo de remielinizacion en enfermedades asociadas con la expresion de la proteina de envoltura herv-w
MX375653B (es) Valvula pretensada para un dispositivo funcional medico y un dispositivo funcional medico.
MX2018010097A (es) Liraglutida en afecciones cardiovasculares.
MX2017014128A (es) 2-tiopirimidinonas.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX393695B (es) Metodos para tratar trastornos de hiperpigmentacion.